Cellules souche et Dérivés

VT107 is a potent pan-TEAD autopalmitoylation inhibitor. VT-107 can be used in cancer therapy research.Cost-effective and quality-assured.

Pentabromophenol (NSC-5717) suppressed TGF-β response by accelerating the turnover rate of TGF-β receptors.

HODHBt is a STAT5-SUMO protein-protein interaction inhibitor.

dCK1α-2 is an orally effective CK1α molecular glue (Molecular Glue) degrader that targets p53 pathway-related targets. It demonstrates antitumor efficacy in mouse models by enhancing the expression of p53-related genes.

GSK-3β inhibitor 11 (compound 21) is a potent inhibitor of glycogen synthase kinase-3β (GSK-3β) with an inhibitory concentration (IC50) of 10.02 μM.

BRD5648 ((R)-BRD0705) is an inactive (R)-enantiomer of BRD0705.

Linavonkibart (SRK181) is a humanized antibody targeting TGFβ1 that blocks the release of TGF-β1 protein by specifically binding latent TGF-β1.

XMU-MP-1 is an inhibitor of the pro-apoptotic, sterile 20-like kinases MST1 and 2.

SSTC3 is a casein kinase 1α (CK1α) activator with potential antitumor activity that inhibits WNT signaling.

Orally active GSK-3 inhibitor 4 targets GSK-3α/β, CDK2/5 (IC50: 0.45-0.68 μM) and may aid in Alzheimer's research by lowering Tau protein.

GSK269962A (GSK269962A HCl) is a selective ROCK(Rho-associated protein kinase) inhibitor with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively.

Akt/ROCK-IN-1 (B12) is a dual inhibitor targeting Akt and ROCK, exhibiting IC50 values of 0.023 nM and 1.47 nM, respectively.

SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3,

Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.

STX-0119 is a selective, orally active STAT3 dimerization inhibitor. STX-0119 inhibits STAT3 transcription with an IC50 of 74 μM.

LY900009 is a small molecule inhibitor of Notch signalling via selective inhibition of the γ-secretase protein.

JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.

CWP232228 is a selective Wnt/β-catenin pathway inhibitor targeting β-catenin/TCF binding, halting breast/liver CSC growth and metastasis safely.

GSK-3 InhibitorXIII, an ATP-competitive GSK-3 inhibitor (Ki: 24 nM), can be used to study diabetes and obesity.

SJ000291942 is an activator of the canonical bone morphogenetic proteins (BMP) signaling pathway.

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mouse GDF10. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Mouse GDF10. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mouse GDF10, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mouse GDF10 in the samples is then determined by comparing the OD of the samples to the standard curve.

Cardiogenol C is a cardiomyogenesis inducer in embryonic stem cells.

NRX-252262 is a potent enhancer of the interaction between β-Catenin, and its cognate E3 ligase, SCFβ-TrCP, induces mutant β-catenin degradation(EC50:3.8 nM)

5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, CDK5/P25 and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase (IC50s

Y-27632 (Y-27632) is an orally potent, ATP-competitive inhibitor of ROCK-I and ROCK-II.

LY3200882 is a highly selective inhibitor of TGF-β receptor type 1 (TGFβRI).

CK2 Inhibitor 2, characterized as a potent, selective, and orally active inhibitor of CK2, demonstrates an impressive IC50 value of 0.66 nM.

Tofacitinib (Tasocitinib) is an orally Janus kinase inhibitor. Tofacitinib is used for the treatment of rheumatoid arthritis. Cost effective and quality assured.

Chromenone 1 is a potent potentiator of osteogenic bone morphogenetic protein (BMP).

ON 108600 is a chemical inhibitor targeting CK2 (Casein Kinase 2), TNIK, and DYRK1, demonstrating IC50 values of 0.016 μM and 0.007 μM for DYRK1A and DYRK1B, 0.

STAT3-IN-35 is a STAT3 inhibitor that binds to the SH2 domain. This compound inhibits the phosphorylation of STAT3 and exhibits antiproliferative activity in triple-negative breast cancer (TNBC) cell lines. Additionally, STAT3-IN-35 has demonstrated toxicity and potent antitumor activity in TNBC xenograft models.

JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).

This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Rat cTnT/TNNT2. Samples (or Standards) are added to the micro ELISA plate wells and combined with the specific antibody and biotinylated detection antibody specific for Rat cTnT/TNNT2. Then Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Rat cTnT/TNNT2, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm. The OD value is proportional to the concentration of Rat cTnT/TNNT2. You can calculate the concentration of Rat cTnT/TNNT2 in the samples by comparing the OD of the samples to the standard curve.

4-Cyanophenacyl bromide, a ketone, used in drug-making and organic synthesis, blocks GSK-3.

TWS119 is a GSK-3β inhibitor; capable of inducing neuronal differentiation

1-Azakenpaullone (azakenpaullone) is a potent and selective GSK-3β inhibitor with IC50 of 18 nM, >100-fold selectivity over CDK1/cyclin B and CDK5/p25.

This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human S100B. Samples (or Standards) are added to the micro ELISA plate wells and combined with the specific antibody and biotinylated detection antibody specific for Human S100B. Then Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human S100B, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm. The OD value is proportional to the concentration of Human S100B. You can calculate the concentration of Human S100B in the samples by comparing the OD of the samples to the standard curve.

PT109 is a multikinase inhibitor that targets JNK and other kinases, playing a crucial role in anti-inflammatory, antioxidative, neurogenic, and synaptogenic processes. Specifically, PT109 inhibits JNK isoforms with the following IC50 values: JNK1 at 0.143 μM, JNK2 at 0.831 μM, and JNK3 at 0.285 μM. It also inhibits SGK isoforms (SGK1: IC50=1.34 μM; SGK2: IC50=5.6 μM; SGK3: IC50=26.4 μM) and ROCK2 (IC50=34 μM). Additionally, PT109 reprograms polymorphic glioblastoma multiforme (GBM) into oligodendroglia via the PTBP1/PKM1/2 pathway and alters the metabolic pattern of GBM to exhibit antiglioma activity.

LP-922056 is an inhibitor of Notum Pectinacetylesterase with EC50 values of 21 nM, 55 nM for human and mouse, respectively.

LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR,

Kaempferol 3-neohesperidoside (Kaempferol 3-O-neohesperidoside), a flavonoid compound, demonstrates an insulinomimetic effect on the rat soleus muscle.

GSK3a-IN-38 is a novel small molecule compound that has inhibitory effects on GSK-3a.

Casein kinase II inhibitor IV is an effective small molecule inducer, which can be used to induce epidermal keratinocyte differentiation.

SH-4-54 is a most potent, small molecule, nonphosphorylated STAT3 inhibitor.

AZD1480: JAK2 inhibitor, IC50 0.26 nM; selective vs Tyk2, JAK3; less on JAK1. Used in solid tumors, PPV, PMF, ET trials.

AS 1892802, a ROCK inhibitor: IC50 - 52nM (hROCK2), 57nM (rROCK2), 122nM (hROCK1). Fast antinociceptive effect similar to Tramadol, Diclofenac.

TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.

EMT inhibitor-1 is an inhibitor of Hippo, Wnt signaling and TGF- macrophages (TGF-) with antitumor activity.

JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nM

Emugrobart is a humanized IgG1κ antibody targeted at GDF8, with HumanIgG1kappa, Isotype Control serving as its corresponding isotype control.

SAG dihydrochloride: potent Smo agonist, activates Hedgehog pathway, counters Cyclopamine. EC50=3 nM, Kd=59 nM.

4-Chloro-2'-bromoacetophenone against glycogen synthase kinase-3 (GSK-3beta).

exo-IWR-1 (exo-IWR 1) is an inactive stereoisomer of Endo-IWR-1,and is a negative control of IWR-1. IWR-1 is a tankyrase inhibitor which inhibits Wnt/β-catenin

1.

JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.

ABC1183, an oral diaminothiazole, inhibits GSK3α/β, CDK9, hinders cancer cell growth, induces G2/M arrest, and modulates phosphorylation.

Jagged-1 (188-204) TFA, a JAG-1 skin protein fragment, induces epidermal maturation and keratinocyte stratification.

Foxy-5 acetate: Wnt 5A agonist, inhibits cancer cell migration/invasion, boosts calcium signaling, doesn't activate β-catenin.

TTP 22: ATP-competitive CK2 inhibitor; IC50/Ki: 0.1 μM/40 nM; >250x selective over JNK3, ROCK1, MET.

Lats-IN-1 is a potent and ATP-competitive Lats1 and Lats2 kinases inhibitor. It promotes Yap-dependent proliferation in postmitotic mammalian tissues.

Stafib-2 is a potent and selective inhibitor of the transcription factor STAT5b.Stafib-2 inhibits STAT5b and STAT5a with IC50 values of 82 nM and 1.7 μM,

Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.

Fasudil (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK.

Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.

Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).

RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.

Baricitinib (INCB028050) is an orally JAK1 and JAK2 inhibitor. Baricitinib has anti-inflammatory and anti-tumor activity. Cost-effective and quality-assured.

Gigantol is a novel inhibitor of the Wnt/β-catenin pathway.